Skip to content

Haemonetics

US · HAE #2165 by market cap Listed 1970
120.16 -0.21 -0.17%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Fair Value how this is computed

Near fair value
42.07 fair value ≈ 86.40 130.72
  • Implied fair-value range of 42.07-130.72, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is +39.1% above the average-multiple fair value of 86.40.

Valuation each multiple against its own 5-year range

P/B ratio 6.23 Expensive vs history 98th percentile
5-year average 4.47 · #98 of 126 in Medical Devices
P/E ratio 54.40 Expensive vs history 78th percentile
5-year average 42.15 · forward 27.47 · #35 of 39 in Medical Devices
P/S ratio 4.05 Expensive vs history 98th percentile
5-year average 3.08 · forward 3.70 · #94 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Haemonetics (HAE) 5.47B 53.17 6.09 0.00%
Abbott Laboratories (ABT) 178.39B 38.29 3.50 2.41%
Medtronic (MDT) 127.84B 24.62 2.54 2.85%
Stryker Corp (SYK) 118.01B 33.01 5.03 1.14%
Boston Scientific (BSX) 60.85B 17.71 2.37 0.00%
Edwards Lifesciences (EW) 58.56B 57.54 5.39 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value131.50 Economic moatNarrow UncertaintyMedium

Trading 9.4% below Morningstar's fair value estimate.

Fair value

Haemonetics Corp earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 7% discount to our quantitative fair value estimate of $131.50 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The company's balance sheet strengthens our estimated fair value. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its current ratio of 2.8, which lies in the top 30% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are undervalued.

On a different note, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 16.5%, for example, ranks in the bottom 20% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Haemonetics discussion 0 comments

Add a comment